BioLineRx Ltd. (TLV:BLRX)
Market Cap | 46.88M |
Revenue (ttm) | 105.41M |
Net Income (ttm) | -33.59M |
Shares Out | 2.23B |
EPS (ttm) | -0.03 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 938,938 |
Average Volume | 4,898,123 |
Open | 2.100 |
Previous Close | 2.100 |
Day's Range | 2.100 - 2.200 |
52-Week Range | 1.400 - 20.800 |
Beta | 0.86 |
RSI | 52.51 |
Earnings Date | May 25, 2025 |
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin les... [Read more]
Financial Performance
In 2024, BioLineRx's revenue was $28.94 million, an increase of 502.92% compared to the previous year's $4.80 million. Losses were -$9.22 million, -84.79% less than in 2023.
Financial numbers in USD Financial StatementsNews
A Look at BioLine Rx's Upcoming Earnings Report
BioLine Rx (NASDAQ: BLRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-27. Here's a quick overview of what investors should know before the release. Analysts are estimating th...
BioLineRx Q1 2025 Earnings Preview
BioLineRx (BLRX) Q1 earnings set for May 27 with EPS estimate at -$1.06 & revenue down 78.4% Y/Y.

BioLineRx to Report First Quarter 2025 Results on May 27, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chie...
BioLineRx GAAP EPS of -$0.01, revenue of $28.94M

BioLineRx Reports 2024 Financial Results and Provides Corporate Update
- Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases - - Executed license agreement with Ayrmid Pharma Ltd. f...
BioLineRx Q4 2024 Earnings Preview
Uncovering Potential: BioLine Rx's Earnings Preview
BioLine Rx (NASDAQ: BLRX) will release its quarterly earnings report on Monday, 2025-03-31. Here's a brief overview for investors ahead of the announcement. Analysts anticipate BioLine Rx to report a...

BioLineRx to Report 2024 Annual Results on March 31, 2025
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Issues Letter to Shareholders
- Company outlines strategic long-term vision and financial outlook - TEL AVIV, Israel , Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical co...
BioLineRx announces change to ratio of ADS to ordinary shares

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
TEL AVIV, Israel , Jan. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, ...

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) rose sharply in today's pre-market trading after the company announced fourth-quarter results . Taiwan Semiconductor Mfg. said...

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday. The Dow traded up 0.08% to 42,765.84 while the NASDAQ gained 1.05% to 19,828.63. ...

Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping more than 200 points on Monday.
BioLineRx announces $10M registered direct offering; shares tumble

BioLineRx Announces $10 Million Registered Direct Offering
TEL AVIV, Israel , Jan. 6, 2025 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapie...
BioLineRx Ltd. (BLRX) Q3 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX) Q3 2024 Earnings Conference Call November 25, 2024 8:30 AM ETCompany ParticipantsJohn Lacey - Head of IR & Corporate...
BioLineRx GAAP EPS of $0.00 beats by $0.07, revenue of $4.94M misses by $0.35M
BioLineRx press release (BLRX): Q3 GAAP EPS of $0.00 beats by $0.07. Revenue of $4.94M misses by $0.35M. As of September 30, 2024, the company had cash,

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
- Executed license agreement with Ayrmid Ltd. for APHEXDA ® (motixafortide) for $10 million upfront, up to $87 million in commercial milestones, and 18-23% tiered royalties on sales - - Received $9 mi...

Earnings Scheduled For November 25, 2024
Companies Reporting Before The Bell • Alarum Technologies (NASDAQ: ALAR) is likely to report quarterly earnings at $0.04 per share on revenue of $7.00 million. • BioLine Rx (NASDAQ: BLRX) is expecte...
BioLineRx Q3 2024 Earnings Preview
BioLineRx (BLRX) is set to report Q3 earnings on Nov 25. Consensus estimates are -$0.11 EPS and $5.29M revenue.
BioLineRx inks licensing deal, share purchase agreement

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% ...

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd.